✅ Model Answer:
• Diagnosis: Acute tubular necrosis (ATN) — intrinsic renal AKI due to nephrotoxic drugs (vancomycin + gentamicin). Elevated creatinine (2.8 from baseline 0.8), elevated BUN (55), BUN/Cr ratio normal (19), elevated urine sodium (52 mEq/L), oliguria (0.4 mL/kg/h). FENa would be >2% (consistent with ATN). Urinalysis would show muddy brown granular casts.
• Any other test: FENa (fractional excretion of sodium) — should be >2% in ATN, urine osmolality (<350 mOsm/kg in ATN), urinalysis (muddy brown casts), serum electrolytes (K, Mg, phosphate), vancomycin trough level, gentamicin peak/trough levels, renal ultrasound (rule out obstruction).
• What to do next: Discontinue nephrotoxic drugs (gentamicin, vancomycin). Avoid other nephrotoxins (NSAIDs, contrast). Fluid management (if oliguric, restrict fluids to insensible losses + urine output). Monitor for hyperkalemia. Consider renal replacement therapy if severe (hyperkalemia >6.5, pulmonary edema, uremic symptoms).
• Follow-up plan: Daily creatinine until recovery. Monitor urine output (goal >1 mL/kg/h). Renal function may recover fully but monitor for CKD. Avoid future nephrotoxic agents. Consider alternative antibiotics (e.g., beta-lactams) for sepsis.

✅ Model Answer:
• Acute Tubular Necrosis (ATN) is a type of intrinsic acute kidney injury characterized by injury and necrosis of renal tubular epithelial cells.
• Causes:
- Ischemic: Prolonged prerenal AKI (hypotension, shock, sepsis, dehydration).
- Nephrotoxic: Medications (aminoglycosides, vancomycin, amphotericin B, cisplatin, contrast agents, NSAIDs).
- Myoglobinuria: Rhabdomyolysis.
- Hemoglobinuria: Hemolysis.
- Endogenous toxins: Uric acid (tumor lysis syndrome), oxalate.
- Infections: Sepsis, acute pyelonephritis.
- Heavy metals: Lead, mercury.
• Pathophysiology: Tubular epithelial cell injury → cell death and sloughing → casts (muddy brown) → tubular obstruction → decreased GFR.
• Risk factors: Sepsis, pre-existing CKD, dehydration, concomitant nephrotoxins.

✅ Model Answer:
• Key differentiating features:
- Prerenal AKI:
• BUN/Cr ratio: >20
• Urine sodium: <20 mEq/L
• FENa: <1%
• Urine osmolality: >500 mOsm/kg
• Urinalysis: Normal
• Response to fluids: Rapid improvement
- ATN (Intrinsic AKI):
• BUN/Cr ratio: 10-20
• Urine sodium: >40 mEq/L
• FENa: >2%
• Urine osmolality: <350 mOsm/kg
• Urinalysis: Muddy brown granular casts
• Response to fluids: No improvement
• Clinical pearl: FENa (fractional excretion of sodium) is the most reliable test. FENa <1% = prerenal; FENa >2% = ATN.

✅ Model Answer:
• Aminoglycosides: Gentamicin, tobramycin, amikacin (most common nephrotoxic antibiotics).
- Mechanism: Accumulate in proximal tubular cells → lysosomal damage → cell necrosis.
- Risk factors: High doses, prolonged therapy, pre-existing renal impairment, dehydration, concomitant vancomycin.
• Vancomycin: Associated with acute kidney injury (especially with high trough levels >15-20 mg/L).
• Amphotericin B: Direct tubular toxicity (fractional excretion of sodium increases).
• NSAIDs: Prostaglandin inhibition → renal vasoconstriction (especially in volume-depleted patients).
• Contrast agents: Iodinated contrast → vasoconstriction and direct tubular toxicity.
• Cisplatin: Chemotherapy → proximal tubular damage.
• Calcineurin inhibitors: Cyclosporine, tacrolimus → vasoconstriction and tubular toxicity.
• Acyclovir: Crystalline nephropathy (precipitates in tubules).
• Methotrexate: Precipitation in tubules (if high doses).

✅ Model Answer:
• Stop nephrotoxic drugs: Discontinue aminoglycosides, vancomycin, NSAIDs, or other nephrotoxins.
• Fluid management:
- If oliguric: Restrict fluids to insensible losses + urine output (to avoid fluid overload).
- If non-oliguric: Maintain euvolemia.
- Avoid overzealous fluid administration.
• Electrolyte management:
- Hyperkalemia: Calcium gluconate, insulin + glucose, albuterol, kayexalate, dialysis if severe.
- Hyponatremia: Correct slowly.
- Hypomagnesemia: Replace if low.
- Hyperphosphatemia: Phosphate binders.
• Acidosis: Sodium bicarbonate if pH <7.2 (or severe).
• Nutritional support: High-calorie, low-protein (if uremic) diet.
• Dialysis (renal replacement therapy):
- Indications: Refractory hyperkalemia, severe acidosis, pulmonary edema, uremic symptoms, progressive azotemia.
- Modalities: Hemodialysis, peritoneal dialysis, CRRT (in critically ill).
• Avoid: Nephrotoxins, contrast agents.

✅ Model Answer:
• Complications:
- Hyperkalemia: Most life-threatening complication (cardiac arrhythmias).
- Fluid overload: Pulmonary edema, hypertension.
- Metabolic acidosis: Due to decreased acid excretion.
- Uremia: Nausea, vomiting, confusion, pericarditis (if severe).
- Hypocalcemia: Due to decreased vitamin D activation.
- Hyperphosphatemia: Decreased excretion.
- Hyponatremia: If free water is given.
- Infections: Increased risk (catheter-related, immunocompromised).
- Chronic kidney disease (CKD): 5-10% of patients with ATN may progress to CKD (especially if severe or prolonged).
- Death: Mortality 5-10% in children (higher if multi-organ failure).

✅ Model Answer:
• Diuretics (loop diuretics, e.g., furosemide):
- Role: Convert oliguric to non-oliguric AKI (increases urine output).
- Not proven to improve renal recovery or reduce mortality.
- May be useful for fluid management (if fluid overload is present).
- Should be used with caution: Can worsen electrolyte imbalances (hypokalemia, hyponatremia).
- Dose: Furosemide 1-2 mg/kg IV (may require higher doses if renal failure).
- Monitoring: Urine output, electrolytes, blood pressure.
- If no response: Consider dialysis (not escalate diuretics).
• Mannitol: Not recommended (increases risk of hyperosmolarity and fluid overload).

✅ Model Answer:
• Prognosis:
- Good: With prompt recognition and removal of the offending agent, most children recover renal function within 2-4 weeks.
- Renal recovery: Usually occurs in the polyuric phase (increased urine output) after the oliguric phase.
- Complete recovery: 80-90% of patients (especially if ATN is drug-induced and treated early).
- Chronic kidney disease: 5-10% may develop CKD (especially if prolonged or severe ATN).
- Mortality: 5-10% in children (higher in critically ill patients with multi-organ failure).
• Long-term follow-up:
- Monitor creatinine: Until baseline is achieved (usually 2-4 weeks).
- Monitor blood pressure: Annually (risk of hypertension).
- Monitor proteinuria: Urine protein/creatinine ratio (if residual damage).
- Avoid nephrotoxins: Future use of aminoglycosides, vancomycin, NSAIDs, and contrast should be minimized.
- Education: Counsel the patient and family about the importance of hydration and avoiding nephrotoxic agents.